A Population-based Investigation of Asthma in the Telemark Region of Norway

October 25, 2022 updated by: Anne Kristin M. Fell, Sykehuset Telemark

Respiratory conditions impose an enormous burden on the individual and the society. According to the WHO World Health Report 2000, the top five respiratory diseases - including asthma and COPD - account for 17% of all deaths and 13% of all Disability-Adjusted Life Years (DALYs). Obstructive lung diseases are among the most common chronic diseases in working-aged populations affecting ~40 million individuals in Europe. The greatest economic burden of respiratory diseases on health services and lost production in the EU is due to COPD and asthma, at about €20 billion each for healthcare and €25 billion and €15 billion, respectively, for lost production.

For Norway, there are no estimates of asthma prevalence for the country as a whole, but 80/1000 women and 55/1000 men used asthma medication in 2013 according to the national prescription register. Estimated annual deaths in Norway due to COPD were 4070 in 2015, which is 30% higher than for lung cancer. Unfortunately, a substantial proportion of patients are still difficult to treat. This underlines the need for better primary prevention and more knowledge regarding causes and exacerbating factors.

Several risk factors for chronic respiratory diseases are identified, most important tobacco smoke, closely followed by air pollution and occupational exposure. However, according to recent reviews there is a lack of understanding regarding environmental risk factors and mechanisms of how these affect respiratory health, the importance of biological markers and comorbidity, and of socioeconomic risk factors. Moreover, there is a need for assessment of interactions between risk factors and between the individual and the environment.

Telemark has a high proportion of craft- and industrial workers providing exposure contrasts. Furthermore, the use of medication against respiratory diseases and the rate of sick leave are higher in Telemark than elsewhere in Norway. Moreover, the county has a high rate of disability. There are previous studies from other parts of Norway, which have estimated the occurrence of respiratory diseases and provided valuable knowledge regarding some risk factors. However, these studies use crude measures of self-reported exposure and do not provide sufficient information on how to target intervention and implement effective prevention. In contrast to the Telemark study, these studies have not included register data or advanced modelling of environmental exposure.

Study Overview

Status

Active, not recruiting

Detailed Description

Hypotheses and choice of methods:

Primary objective:

To identify preventive and health promoting measures for obstructive respiratory disease in a 5-year follow up of adults from the general population in Telemark.

Secondary objectives:

  • Identify occupational risk factors for obstructive respiratory disease
  • Assess interactions between risk factors and the individual
  • Transfer relevant knowledge and advice regarding preventive and health promoting measures to individuals, health care professionals and authorities.

Research problems/questions (Q):

Q1 What are the emerging occupational risk factors for respiratory health? Q2 What are the social inequity/socioeconomic factors predicting respiratory disease? Q3 How does HRQoL develop over time? Q4 Do risk factors interact and how do they relate to the individual? Q5 What is the population attributable risk (PAR) for the identified risk factors, and what are the key factors for better prevention and respiratory health promotion?

Choice of methods/work packages (WP) and approaches (A):

WP I Occupational risk factors Q1 Emerging occupational causes and risk factors for respiratory disease and exacerbation

  • A1.1 Assess associations between self-report of occupational exposure and new-onset and exacerbation of respiratory symptoms and diseases
  • A1.2 Assess associations between job-exposure-matrix data (JEM) and new-onset and exacerbation of respiratory symptoms and diseases

WP II Individual risk factors Q2 Risk factors for social inequity in respiratory health

• A2.1 Assessment of the association between socio-demographic variables (gender, age, education, occupation and income) and respiratory health

WP III Complex interactions Q3 Health related quality of life development over time.

  • A3.1 Impact of respiratory health and disease development and treatment on HRQoL development Q4 Interactions between risk factors and the individual
  • A4.1 Identify interactions between risk factors and the individual by using advanced mathematical modelling Q5 The population attributable risk (PAR) for identified risk factors and key factors for better prevention and respiratory health promotion
  • A5.1 Calculate PAR for risk factors identified in WP1-3 separately and combined
  • A5.2 Based on PAR, estimate key factors for prevention and their cost

Study Type

Observational

Enrollment (Anticipated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Telemark
      • Skien, Telemark, Norway, 3710
        • Telemark Hospital, dep. of Occupational and Environmental Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 50 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The researchers collected data in 2013 on respiratory symptoms and physician diagnosed asthma from 16.099 inhabitants of Telemark County (the cross-sectional baseline study called The Telemark-study I). A random sample from the baseline study of approximately 650 asthma cases and 650 controls were asked to take part in a medical examination in a case-control study in 2014-15.

The five year follow up of the baseline (The Telemark-study II) study was performed in 2018 and included 13500 subjects. The follow-up of the nested case-control study started in September 2018 and is on-going.

Description

Inclusion Criteria:

  • Physician diagnosed asthma
  • Controls without physician-diagnosed asthma

Exclusion Criteria:

  • inability to fill-inn the questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The occurence of asthma and the association to specific occupational and environmental exposures and comorbidity
Time Frame: Five years
Incidence and associations
Five years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Risk factors for the occurence of asthma symptoms in subjects with asthma symptoms but no asthma diagnosis
Time Frame: Five years
Odds ratio
Five years
Differences in lung function, FeNO and inflammatory markers in blood in asthma patients and the association of these changes to specific occupational and environmental exposures.
Time Frame: Five years
Lung function indices, serum levels in blood
Five years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Johny Kongerud, Professor, Oslo University, Oslo University Hospital
  • Principal Investigator: Anne Kristin Møller Fell, PhD, Sykehuset Telemark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2018

Primary Completion (Anticipated)

December 31, 2035

Study Completion (Anticipated)

December 31, 2035

Study Registration Dates

First Submitted

February 20, 2014

First Submitted That Met QC Criteria

February 25, 2014

First Posted (Estimate)

February 27, 2014

Study Record Updates

Last Update Posted (Actual)

October 26, 2022

Last Update Submitted That Met QC Criteria

October 25, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation

3
Subscribe